Events |

MSF Oxfam Vaccine Consultation Agenda

VACCINES

Médecins Sans Frontières & Oxfam Consultation
26 January 2010, Geneva, Switzerland
 

Improving access and stimulating vaccine development for use in resource-poor settings

Agenda

9.00am – 9.30am: Welcome and context

1. Introduction on the goals & objectives of the meeting: time for a paradigm shift?
Tido von Schoen-Angerer, MSF

2. Highlights of MSF/Oxfam commissioned assessment of current access and R&D environment 
Paul Wilson, Consultant

9.30am – 11.00am: Roundtable I: Challenges to the development of adapted and affordable vaccines - Case studies
Moderator: Simonetta Viviani

1. Case study: heat-stable vaccine technologies. Opportunities and bottlenecks for development, introduction, and adoption
Modibo Dicko, WHO

  • Progress to date
  • Challenges, e.g. regulatory, policy, financing, commercial market
  • What enabling environment is needed to make optimal progress

2. Case study: Rotavirus and PCV: Appropriateness of vaccines developed for global vaccine market
Rebecca Grais, Epicentre

  • Vaccine composition: Inclusion of rotavirus genotypes that are most common in sub-Saharan Africa in current vaccines
  • Programmatic challenges to administer recommended doses of rotavirus and PCV; possible impact on existing vaccine activities
  • How a vaccine targeting countries with highest disease burden should/could have been developed Discussion


11:00am – 11:30 am: Coffee break
11:30am – 1:00 pm: Roundtable II: Access to newer vaccines

Moderator: Diane Griffin, Johns Hopkins University

1. Opportunities and challenges with introduction of newer vaccines: what is needed from the next generation of vaccines?
Samba Sow, Director Mali Center for Vaccine Development

  • Lessons learnt from HIB and penta introduction
  • Anticipated challenges with pneumo, rotavirus and MenA conjugate introduction
  • Balancing opportunities from new vaccines and possible disturbances of current vaccine activities
  • Essential requirements for new vaccines in terms of epidemiology, presentation

2. New regulatory pathway for vaccine registration
Gillian Chaloner-Larsson

  • What regulatory challenges exist that could prevent speedy registration of such products
  • Solutions that can be envisioned

3. Financial sustainability of the current model to introduce new vaccines: What is needed to create a more enabling environment?
Lidija Kamara, WHO

  • Current market dynamics and vaccine financing models
  • Tiered pricing, theory and practice
  • Potential of developing country manufacturers to contribute to development and production of better adapted and more affordable vaccines Discussion


1:00pm – 2:00 pm: Lunch
2:00pm – 4:00 pm: Roundtable III: Existing and new ways to support technology transfer and implementation science

Introduction and moderator: Marie-Paule Kieny, WHO

1. Introduction: different current and possible models
Presented by moderator

2. Project managed approach: Meningitis A conjugate example
Marc Laforce, PATH

3. NVI experience and concept of central technology hub
Jan Hendriks, NVI

4. Lessons learnt from cholera vaccine development
Rodney Carbis, IVI

5. Benefit sharing and dealing with IP and technology transfer issues in the context of influenza virus
Sangeeta Shashikant, TWN Discussion:

  • Strengths and weaknesses of models
  • Creating new permanent initiatives and solutions?

4:00pm – 4:30 pm: Coffee break
4:30pm – 6:00 pm: Roundtable III (cont.) New strategies and next steps

Moderator: Rohit Malpani, Oxfam

1. Sustainable funding streams and innovative mechanisms to stimulate needs based R&D
Laurent Gadot, MSF

Discussion:

  • What issues are not so far covered but are considered important?
  • What are the key conclusions of the meeting?
  • Potential next steps